211 filings
Page 8 of 11
8-K
g7t8 20va0yvx
4 Mar 19
Entry into a Material Definitive Agreement
4:54pm
424B5
6eea2
28 Feb 19
Prospectus supplement for primary offering
4:55pm
8-K
ona3utt8 9l
28 Feb 19
Other Events
4:06pm
8-K
c6dp fgsx
4 Jan 19
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
7:05am
8-K
zsyk nqtjb
4 Jan 19
Termination of a Material Definitive Agreement
7:05am
8-K
ljaju xrb
13 Nov 18
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
7:10am
EFFECT
0c2labrz1dx 4n
17 Sep 18
Notice of effectiveness
12:00am
8-K
gq0tmqrlfm9z5ix
17 Sep 18
Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522
12:00am
CORRESP
sw02l0
12 Sep 18
Correspondence with SEC
12:00am
8-K
dmyiwtf 616f
14 Aug 18
Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates
4:24pm
8-K
zf8o96bj
23 Jul 18
Mersana Therapeutics Announces Partial Clinical Hold for XMT-1522 Clinical Trial
5:09pm
CORRESP
cpi9x77h
16 Jul 18
Correspondence with SEC
12:00am
S-3/A
ilejyw 6g73
12 Jul 18
Shelf registration (amended)
4:23pm
CORRESP
megotdalk1kfdy2gyl
12 Jul 18
Correspondence with SEC
12:00am
CORRESP
gchbqk8
12 Jul 18
Correspondence with SEC
12:00am
UPLOAD
7spu0kp9vuko g9
11 Jul 18
Letter from SEC
12:00am
S-3
raqrukpovfy9sncvcw5
2 Jul 18
Shelf registration
5:27pm